JPWO2021182572A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021182572A5
JPWO2021182572A5 JP2021531943A JP2021531943A JPWO2021182572A5 JP WO2021182572 A5 JPWO2021182572 A5 JP WO2021182572A5 JP 2021531943 A JP2021531943 A JP 2021531943A JP 2021531943 A JP2021531943 A JP 2021531943A JP WO2021182572 A5 JPWO2021182572 A5 JP WO2021182572A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
chain variable
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021531943A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021182572A1 (https=
JP7793985B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2021/009797 external-priority patent/WO2021182572A1/ja
Publication of JPWO2021182572A1 publication Critical patent/JPWO2021182572A1/ja
Publication of JPWO2021182572A5 publication Critical patent/JPWO2021182572A5/ja
Application granted granted Critical
Publication of JP7793985B2 publication Critical patent/JP7793985B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021531943A 2020-03-12 2021-03-11 癌の治療及び/又は予防のための医薬品 Active JP7793985B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020043020 2020-03-12
JP2020043020 2020-03-12
PCT/JP2021/009797 WO2021182572A1 (ja) 2020-03-12 2021-03-11 癌の治療及び/又は予防のための医薬品

Publications (3)

Publication Number Publication Date
JPWO2021182572A1 JPWO2021182572A1 (https=) 2021-09-16
JPWO2021182572A5 true JPWO2021182572A5 (https=) 2024-02-28
JP7793985B2 JP7793985B2 (ja) 2026-01-06

Family

ID=77670688

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021531943A Active JP7793985B2 (ja) 2020-03-12 2021-03-11 癌の治療及び/又は予防のための医薬品

Country Status (7)

Country Link
US (1) US20230140155A1 (https=)
EP (1) EP4119159A4 (https=)
JP (1) JP7793985B2 (https=)
KR (1) KR20220153615A (https=)
BR (1) BR112022018171A2 (https=)
CA (1) CA3175129A1 (https=)
WO (1) WO2021182572A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101638490B1 (ko) * 2008-08-05 2016-07-11 도레이 카부시키가이샤 암의 치료 및 예방용 의약 조성물

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
CA2194907A1 (en) 1994-07-13 1996-02-01 Kouji Matsushima Reshaped human antibody against human interleukin-8
US6677436B1 (en) 1998-04-03 2004-01-13 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス,インコーポレーテッド 変異型Fc領域を含む抗体の同定および作製ならびにその利用法
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
DE10359795A1 (de) 2003-12-19 2005-07-21 Bayer Technology Services Gmbh Strangverdampfervorrichtung
KR101638490B1 (ko) 2008-08-05 2016-07-11 도레이 카부시키가이샤 암의 치료 및 예방용 의약 조성물
AU2010270979B2 (en) 2009-06-22 2015-04-23 Medimmune, Llc Engineered Fc regions for site-specific conjugation
SG178925A1 (en) 2009-09-22 2012-04-27 Volker Sandig Process for producing molecules containing specialized glycan structures
BR112012018943A8 (pt) 2010-02-04 2017-12-19 Toray Industries medicamento e método para o tratamento e/ou prevenção de um câncer
KR101842893B1 (ko) 2010-02-04 2018-03-28 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
RU2598258C2 (ru) 2010-02-04 2016-09-20 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
MX342291B (es) 2010-02-04 2016-09-23 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
HUE025678T2 (en) * 2010-02-04 2016-04-28 Toray Industries A pharmaceutical composition for the treatment and / or prevention of cancer
MX340015B (es) 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
BR112012024489A2 (pt) 2010-03-29 2016-05-31 Zymeworks Inc anticorpos com função efetora suprimida ou aumentada
JP6070191B2 (ja) 2011-08-04 2017-02-01 東レ株式会社 癌の治療及び/又は予防用医薬組成物
PT2740794T (pt) 2011-08-04 2018-06-14 Toray Industries Composição farmacêutica para o tratamento e/ou profilaxia de cancro
US9181348B2 (en) 2011-08-04 2015-11-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
KR102041832B1 (ko) 2011-08-04 2019-11-08 도레이 카부시키가이샤 췌장암의 치료 및/또는 예방용 의약 조성물
RU2595400C2 (ru) 2011-08-04 2016-08-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
PT2740793T (pt) 2011-08-04 2018-02-23 Toray Industries Composição de fármacos para o tratamento e/ou a prevenção de cancro
HUE044611T2 (hu) 2012-02-21 2019-11-28 Toray Industries Gyógyászati készítmény rák kezelésére
US9260513B2 (en) 2012-02-21 2016-02-16 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
BR112014021103A2 (pt) 2012-02-21 2019-10-15 Toray Industries, Inc Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
PT2818483T (pt) 2012-02-21 2017-10-09 Toray Industries Composição medicinal para tratamento e/ou prevenção de cancro
KR102155531B1 (ko) * 2012-03-30 2020-09-15 도레이 카부시키가이샤 간암의 치료 및/또는 예방용 의약 조성물
PT2832366T (pt) 2012-03-30 2018-01-25 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção de cancro de vesícula biliar
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
ES2704909T3 (es) 2013-08-09 2019-03-20 Toray Industries Composición farmacéutica para el tratamiento y/o la prevención del cáncer
CN107106688A (zh) * 2014-11-14 2017-08-29 豪夫迈·罗氏有限公司 预测对vegf拮抗剂的响应
KR20240005247A (ko) * 2016-10-28 2024-01-11 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
JP7342701B2 (ja) * 2018-03-30 2023-09-12 東レ株式会社 癌の治療及び/又は予防用医薬組成物
JP7279323B2 (ja) 2018-09-12 2023-05-23 日産自動車株式会社 燃料電池システム

Similar Documents

Publication Publication Date Title
JPWO2021182573A5 (https=)
EP3777888A1 (en) Pharmaceutical composition for treatment and/or prevention of cancer
CN119789868A (zh) 用于癌的治疗和/或预防的药品
EP4119156A1 (en) Medicament for treatment and/or prevention of cancer
US20250228937A1 (en) Medicament for treatment and/or prevention of cancer
JPWO2021182571A5 (https=)
JPWO2021182574A5 (https=)
JPWO2021182570A5 (https=)
JPWO2021182572A5 (https=)
JP7715041B2 (ja) 癌の治療及び/又は予防のための医薬品
JP7793986B2 (ja) 癌の治療及び/又は予防のための医薬品
US20230159635A1 (en) Medicament for treatment and/or prevention of cancer
JP7793985B2 (ja) 癌の治療及び/又は予防のための医薬品
WO2023073429A1 (en) Methods of using anti-egf antibodies to augment the activity of braf and kras inhibitors
WO2019107341A1 (ja) オゾンナノバブルの抗がん剤
EP4360648A1 (en) Medicament for treatment and/or prevention of cancer
US20260115285A1 (en) Medicament for treatment and/or prevention of cancer
EP4582101A1 (en) Medicament for treatment and/or prevention of cancer
US20260115267A1 (en) Methods of using anti-egf antibodies to augment the activity of braf and kras inhibitors
EP4578457A1 (en) Pharmaceutical for treating and/or preventing cancer
EP4578458A1 (en) Medicament for treatment and/or prevention of cancer
EP4578459A1 (en) Pharmaceutical product for treatment and/or prevention of cancer
EP4640235A1 (en) Medicament for treatment and/or prevention of cancer